Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,304 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sclerostin: a possible target for the management of cancer-induced bone disease.
Gkotzamanidou M, Dimopoulos MA, Kastritis E, Christoulas D, Moulopoulos LA, Terpos E. Gkotzamanidou M, et al. Among authors: dimopoulos ma. Expert Opin Ther Targets. 2012 Aug;16(8):761-9. doi: 10.1517/14728222.2012.697154. Epub 2012 Jul 5. Expert Opin Ther Targets. 2012. PMID: 22762409 Review.
Pathogenesis and management of myeloma bone disease.
Christoulas D, Terpos E, Dimopoulos MA. Christoulas D, et al. Among authors: dimopoulos ma. Expert Rev Hematol. 2009 Aug;2(4):385-98. doi: 10.1586/ehm.09.36. Expert Rev Hematol. 2009. PMID: 21082944 Review.
Advances in imaging and the management of myeloma bone disease.
Terpos E, Moulopoulos LA, Dimopoulos MA. Terpos E, et al. Among authors: dimopoulos ma. J Clin Oncol. 2011 May 10;29(14):1907-15. doi: 10.1200/JCO.2010.32.5449. Epub 2011 Apr 11. J Clin Oncol. 2011. PMID: 21483016 Review.
Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy.
Terpos E, Christoulas D, Katodritou E, Bratengeier C, Gkotzamanidou M, Michalis E, Delimpasi S, Pouli A, Meletis J, Kastritis E, Zervas K, Dimopoulos MA. Terpos E, et al. Among authors: dimopoulos ma. Int J Cancer. 2012 Sep 15;131(6):1466-71. doi: 10.1002/ijc.27342. Epub 2011 Dec 21. Int J Cancer. 2012. PMID: 22052418
Prevention and treatment of myeloma bone disease.
Terpos E, Kastritis E, Dimopoulos MA. Terpos E, et al. Among authors: dimopoulos ma. Curr Hematol Malig Rep. 2012 Dec;7(4):249-57. doi: 10.1007/s11899-012-0135-0. Curr Hematol Malig Rep. 2012. PMID: 22941027 Review.
Current treatments for renal failure due to multiple myeloma.
Kastritis E, Terpos E, Dimopoulos MA. Kastritis E, et al. Among authors: dimopoulos ma. Expert Opin Pharmacother. 2013 Aug;14(11):1477-95. doi: 10.1517/14656566.2013.803068. Epub 2013 May 25. Expert Opin Pharmacother. 2013. PMID: 23705905 Review.
Emerging treatment approaches for myeloma-related bone disease.
Gavriatopoulou M, Dimopoulos MA, Kastritis E, Terpos E. Gavriatopoulou M, et al. Among authors: dimopoulos ma. Expert Rev Hematol. 2017 Mar;10(3):217-228. doi: 10.1080/17474086.2017.1283213. Epub 2017 Jan 29. Expert Rev Hematol. 2017. PMID: 28092987 Review.
1,304 results